Dynavax inks universal vaccine pact with Novartis

Dynavax Technologies and Novartis Vaccines and Diagnostics are teaming up on an effort to develop a new universal flu vaccine. Novartis Vaccines, which includes the old Chiron ops it bought out, will provide a trivalent flu vaccine to Dynavax for use in the universal vaccine in exchange for an exclusive option to negotiate a licensing deal. No financial details were divulged in their announcement.

Vaccine makers have been scrambling to come up with a universal flu vaccine that can defend against a variety of flu strains. Every year health officials target three strains--a guessing game that often misses the mark. A universal vaccine would help remove some of that guesswork and do a much better job at protecting populations

- read the report from the San Francisco Business Times

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.